Facing the Challenge of Acne Vulgaris in Pediatric Patients

 

A CME-certified supplement to Pediatric News.
This supplement is supported by an educational grant from Ortho Dermatologics, and jointly sponsored by University of Louisville Continuing Health Sciences Education Skin Disease Education Foundation, an Elsevier business.

This continuing medical education (CME) supplement was developed from a clinical roundtable held during Skin Disease Education Foundation's 34th Hawaii Dermatology Seminar CME conference, Waikoloa, Hawaii, February 14-19, 2010.

•Faculty
•Topic Highlights
•Target Audience
•Statement of Professional Practice Gap(s)
•Learning Objectives
•Disclosure
•Accreditation

To view the supplement, click the image above.
Faculty

 

 

 

 

 

 

Chair
Lawrence F. Eichenfield, MD
Chief of Pediatric and Adolescent Dermatology
Professor of Pediatrics and Medicine (Dermatology)
Rady Children's Hospital
UCSD School of Medicine
San Diego, CA

Joseph E. Fowler, Jr., MD
Clinical Professor of Dermatology
University of Louisville
Louisville, KY

Richard G. Fried, MD, PhD
Private Practice
Yardley Dermatology Associates
Yardley, PA

Sheila F. Friedlander, MD
Professor of Clinical Medicine, Pediatrics & Dermatology
Rady Children's Hospital
UCSD School of Medicine
San Diego, CA

Moise L. Levy, MD
Specially for Children
Chief, Pediatric Dermatology
Dell Children's Medical Center
Austin, TX
Clinical Professor, Dermatology/Pediatrics
Baylor College of Medicine
Houston, TX

Guy F. Webster, MD, PhD
Clinical Professor
Department of Dermatology
Jefferson Medical College
Philadelphia, PA

Topic Highlights

• Introduction
• Acne Epidemiology and Pathophysiology
• Diagnosis and Evaluation of Acne
• Medical and Psychosocial Impact of Acne
• Perspectives on Therapeutic Options for Acne: An Update

Target Audience

 

 

 

 

 

 

The target audiences for this educational supplement are dermatologists, pediatricians, and other health care professionals involved in the treatment of pediatric patients with acne.
Statement of Professional Practice Gap(s)

 

 

 

 

 

 

Untreated or ineffectively managed acne vulgaris is associated with important physical and psychosocial sequelae. The wide range of topical and systemic treatments allows clinicians to choose a regimen that is appropriate for each patient. Further, with appropriate treatment, acne can be successfully managed in almost every case. The articles in this supplement provide an update on the epidemiology, pathophysiology, medical and psychosocial impact, and treatment of acne vulgaris in pediatric patients. As much of the most recent new information on acne concerns an emerging subgroup-that is, children between about 8 and 11 years of age-evidence and insights about younger patients are presented and discussed. Clinicians who provide health care to pediatric patients with acne must have the latest clinical data and knowledge to individualize their patients' care.
Learning Objectives

 

 

 

 

 

Upon completion of this activity, participants will be better able to:
• Assess and classify acne vulgaris in pediatric patients.
• Describe the topical and systemic medications available and suitable for use in pediatric patients with acne.
• Determine the type of medication and route of delivery appropriate for individual patients, based on age, severity of disease, and other factors.
• Counsel patients and parents regarding the management of the disease and review strategies for coping with acne.
Disclosure

 

 

 

 

 

As a sponsor accredited by the ACCME, the CHSE must ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty participating in this CME activity were asked to disclose the following:
• Names of proprietary entities producing health care goods or services-with the exemption of nonprofit or government organizations and non-health-related companies-with which they or their spouse/partner have, or have had, a relevant financial relationship or have had a relevant financial relationship within the past 12 months. For this purpose, we consider the relevant financial relationships of a spouse/partner of which they are aware, to be their financial relationships.
• Describe what they or their spouse/partner received (salary, honorarium, etc).
• Describe their role.
• Declare no relevant financial relationships.

Lawrence F. Eichenfield, MD, has served as a speaker for Coria. He has also been an investigator and/or consultant for Johnson & Johnson, Ortho Dermatologics, Stiefel, Galderma, and sanofi-aventis.

Joseph F. Fowler, Jr, MD, has been a consultant for Galderma, Graceway, Hyland, Johnson & Johnson, Quinnova, Ranbaxy, Shire, Stiefel, Triax, and Valeant. He has been a speaker for Galderma, Medicis, Ranbaxy, Shire, Stiefel, UCB, and Valeant. He has also been an investigator for Abbott, Taro, Allerderm, Allergan, Amgen, Astellas, Centocor, Coria, Dermik, Dow, Galderma, Genentech, Johnson & Johnson, Medicis, Novartis, Quinnova, Shire, Stiefel, Taisho, and 3M.

Richard G. Fried, MD, PhD, has nothing to disclose.

Sheila F. Friedlander, MD, has been a consultant for Astellas, Barrier Therapeutics, Galderma, Graceway, Novartis, and sanofi-aventis. She has also received grant research support from Atlanta, Amgen, Astellas, Barrier Therapeutics, Galderma, Hill Dermaceuticals, Johnson & Johnson, LEO Pharmaceuticals, Novartis, Ortho Dermatologics, Photocure, Pierre-Fabre, RegeneRx, and Dow.

Moise L. Levy, MD, has been a consultant for GlaxoSmithKline and SkinMedica.

Sylvia Reitman, MBA, has nothing to disclose.

Joanne Still has nothing to disclose.

Guy F. Webster, MD, PhD, has been a consultant for Allergan, Cutanea, Cipher, Galderma, GlaxoSmithKline, Medicis, Ortho, and Quinnova.

CHSE Committee Members have no relevant financial relationships with any commercial interests: Carolyn Burns, MD; Dedra DeBerry, MA; Joyce Dunagan, MA, MSLS; Linda H. Freeman, DNS, RN; Paul Fultz; Terri Gipson, MSL; Ruth Greenberg, PhD; Lucy Juett, MS; Irene Litvan, MD; Loretta Maldaner; Mike Mansfield, DMD; Ashlee Melendez, RN, BSN; Lisa J. Pfitzer, MD; Robert Sexton, MD; Uldis Streips, PhD; Kathy M. Vincent, MD; Lori Wagner, MD; Stephen Wheeler, MD; Sharon K. Whitmer, EdD.
Accreditation

 

 

 

 

 

 

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Louisville School of Medicine Continuing Health Sciences Education (CHSE) and the Global Academy for Medical Education, LLC, an Elsevier business. CHSE is accredited by the ACCME to provide continuing medical education for physicians.

CHSE designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Term of Approval: June 2010 - June 30, 2012.

Copyright © 2010 by Elsevier Inc.

---